Late-stage pharmaceutical company Citius Pharmaceuticals, Inc. is a major innovator in the development and commercialization of critical care products. Covering a wide array of medical solutions, the company's products focus on various oncology-related issues, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. Citius Pharmaceuticals is currently at work on five proprietary products of its own, including I/ONTAK, a cutting-edge engineered IL-2 diphtheria toxin fusion protein designed to treat patients with persistent or recurrent cutaneous T-cell lymphoma. The company's Mino-Lok is a groundbreaking antibiotic lock solution that combats catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido, another Citius Pharmaceuticals project, is a cutting-edge corticosteroid-lidocaine topical formulation designed to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap, the company's liquifying gel-based wrap for the reduction of tissue expander infections following breast reconstructive surgeries, promises to be a game-changer in the field of patient recovery. Finally, NoveCite, a proprietary mesenchymal stem cell therapy, holds the potential for revolutionary treatments in the area of acute respiratory disease syndrome. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals was founded in 2007 and is poised to make major contributions to the advancement of critical care products.
Citius Pharmaceuticals, Inc.'s ticker is CTXR
The company's shares trade on the NASDAQ stock exchange
They are based in Cranford, New Jersey
There are 1-10 employees working at Citius Pharmaceuticals, Inc.
It is https://www.citiuspharma.com/
Citius Pharmaceuticals, Inc. is in the Healthcare sector
Citius Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are Citius Pharmaceuticals, Inc.'s industry peers: